EOG Resources, Inc. (EOG) continued its upward trend with the stock climbing 0.08% or $0.08 to close the day at $103.62 on light trading volume of 2.42M shares, compared to its three month average trading volume of 3.46M. The Houston Texas 77002 based company has been outperforming the independent oil & gas group over the past 52 weeks, with the stock gaining 49.03%, compared to the industry which has advanced 33.2% over the same period. With RSI of 57.77, the stock should still continue to rise and get closer to its one year target estimate of $109.92, making it a hold for now.
EOG Resources, Inc., together with its subsidiaries, explores for, develops, produces, and markets crude oil and natural gas. The companys principal producing areas are located in New Mexico, North Dakota, Texas, Utah, and Wyoming in the United States; and Canada, the Republic of Trinidad and Tobago, the United Kingdom, and the People’s Republic of China. As of December 31, 2015, it had total estimated net proved reserves of 2,118 million barrels of oil equivalent, including 1,098 million barrels (MMBbl) crude oil and condensate reserves; 383 MMBbl of natural gas liquid reserves; and 3,825 billion cubic feet of natural gas reserves. EOG Resources, Inc. was founded in 1985 and is headquartered in Houston, Texas.
CME Group Inc. (CME) grew with the stock adding 0.98% or $1.12 to close at $115.52 on active trading volume of 2.4M compared its three months average trading volume of 1.69M. The Chicago Illinois 60606 based company operating under the Investment Brokerage – National industry has been trending up for the last 52 weeks, with the shares price now 35.97% up for the period and up by 0.15% so far this year. With price target of $120.59 and a 48.43% rebound from 52-week low, CME Group Inc. has plenty of upside potential, making it a hold with a view buy.
CME Group Inc., through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. The company offers a range of products across various asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals. Its products include exchange-traded; and privately negotiated futures and options contracts and swaps. It executes trade through its electronic trading platforms, open outcry, and privately negotiated transactions, as well as provides hosting, connectivity, and customer support for electronic trading through its co-location services. The company also provides clearing and settlement services for exchange-traded contracts, as well as for cleared swaps; and regulatory reporting solutions for market participants through its global repository services in the United States, the United Kingdom, Canada, and Australia. In addition, the company offers a range of market data services, including live quotes, delayed quotes, market reports, and historical data service, as well as index services. CME Group Inc. serves professional traders, financial institutions, institutional and individual investors, corporations, manufacturers, producers, governments, and central banks. The company was formerly known as Chicago Mercantile Exchange Holdings Inc. and changed its name to CME Group Inc. in July 2007. CME Group Inc. was founded in 1898 and is headquartered in Chicago, Illinois.
OvaScience, Inc. (OVAS) continued its upward trend with the stock climbing 2.94% or $0.05 to close the day at $1.75 on lower than average trading volume of 2.37M shares, compared to its three month average trading volume of 924.05K. The Waltham Massachusetts 02451 based company has been outperforming the biotechnology companies by -76.1509% for last three months and its recent losses have trimmed gains to 14.38% YTD, versus the biotechnology industry which is up 2.5% for the same period. The RSI of 29.03 indicates the stock is oversold at the current levels, buy for now.
OvaScience, Inc., a fertility company, discovers, develops, and commercializes new fertility treatment options for women worldwide. The companys patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman’s own ovaries. It engages in developing and commercializing various fertility treatment options designed to enhance egg health and revolutionize in vitro fertilization (IVF) consisting of AUGMENT to enhance the energy and health of the womans eggs by using mitochondria from a woman’s EggPC cells; OvaPrime treatment is used to replenish a woman’s egg reserve by transferring the EggPCs from woman’s own ovaries; OvaTure to produce mature fertilizable eggs from a womans own EggPC cells without the need for hormone injections; and OvaXon for the prevention of genetic disease and animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.